| ²é¿´: 355 | »Ø¸´: 1 | |||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | |||
wqssfj1Ìú¸Ëľ³æ (ÖøÃûдÊÖ)
|
[ÇóÖú]
ÇóÖú·Òë
|
||
|
The CDS displays the company¡¯s current position on important characteristics of the product, including the Core Safety Information according to ICH E2C. The CDS contains all relevant information relating to indications, dosing, pharmacovigilance and Core Safety Information which Novartis requires to be listed for the product in all countries where the product is registered. лл£¡ |
» ²ÂÄãϲ»¶
327Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
08¹¤¿ÆÇóµ÷¼Á290·Ö
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸985³õÊÔ354·ÖÉúÎïµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸2110£¬»¯Ñ§Ñ§Ë¶310·Ö£¬±¾¿ÆÖصãË«·ÇÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
353Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
334Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
Ò»Ö¾Ô¸0807 ÊýÒ»Ó¢Ò» 313 ÓÐûÓжþÂÖµ÷¼Á
ÒѾÓÐ7È˻ظ´
¸´ÊÔµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤289·Ö
ÒѾÓÐ14È˻ظ´
086000µ÷¼Á
ÒѾÓÐ3È˻ظ´
yuanbing0000
ÖÁ×ðľ³æ (СÓÐÃûÆø)
- ·ÒëEPI: 21
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 13255.2
- ºì»¨: 1
- Ìû×Ó: 81
- ÔÚÏß: 70.3Сʱ
- ³æºÅ: 1143224
- ×¢²á: 2010-11-10
- ÐÔ±ð: MM
- רҵ: ´«¶¯»úеѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ(½ð±Ò+1): 2012-02-29 21:12:44
sltmac(½ð±Ò+7, ·ÒëEPI+1): 2012-03-10 09:37:47
°®ÓëÓêÏÂ(½ð±Ò+1): 2012-02-29 21:12:44
sltmac(½ð±Ò+7, ·ÒëEPI+1): 2012-03-10 09:37:47
|
ÎÒÀí½âµÄÒâ˼ÈçÏ£º ¸ù¾ÝÈËÓÃÒ©Æ·×¢²á¼¼Êõ¹æ¶¨¹ú¼Êе÷»áÒéÖÐÉÏÊÐÒ©Æ·¶¨ÆÚ°²È«ÐÔ¸üб¨¸æµÄºËÐݲȫÐÅÏ¢£¬±àÂëÐòÁÐÏÔʾÁ˹«Ë¾Ä¿Ç°ÔÚ²úÆ·ÖØÒªÐÔ·½ÃæËù´¦µÄµØÎ»¡£ ±àÂëÐòÁк¸ÇËùÓÐÓëÊÊÓ¦Ö¢¡¢¼ÁÁ¿¡¢Ò©Îᆵ½äÒÔ¼°»ù´¡°²È«ÐÅÏ¢Ïà¹ØµÄ×ÊÁÏ¡£Åµ»ªÒªÇóÔÚ×¢²áÁ˸òúÆ·µÄËùÓйú¼ÒÁгö²úÆ·µÄÕâЩÐÅÏ¢¡£ |
2Â¥2012-02-29 20:37:10













»Ø¸´´ËÂ¥